Aprogen Biologics Inc.
Financials
Valuation Metrics
Aprogen Biologics Inc.'s Market Cap is ₩326B. At end of 2025 it was ₩75B. Ranked #2015 of 2,436 in KR market (top 83%), #738 of 787 on KOSPI (top 94%), #214 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 32.57B KRW | KR#2,015/2,436 Sec#214/234 |
| Revenue | 78.00B KRW | KR#1,548/2,436 Sec#99/234 |
| Net Income | -129.81B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 576.99B KRW | KR#678/2,436 Sec#38/234 |
| Net Assets | 272.85B KRW | KR#741/2,436 Sec#49/234 |
| Employees | 427 | KR#572/2,436 Sec#46/234 |
| Value | ||
| P/B | 0.12x | KR#18/2,436 Sec#2/234 |
| P/S | 0.42x | KR#796/2,436 Sec#23/234 |
| FCF Yield | -146.93% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -47.58% | KR#2,260/2,436 Sec#196/234 |
| ROA | -22.50% | KR#2,248/2,436 Sec#182/234 |
| Op. Margin | -74.66% | KR#2,282/2,436 Sec#167/234 |
| Revenue Growth | 28.33% | KR#505/2,436 Sec#47/234 |
| Financial Health | ||
| Debt Ratio | 211.47% | KR#1,790/2,436 Sec#194/234 |
| Total Debt | 332.48B KRW | KR#371/2,436 Sec#19/234 |
| FCF | -47.86B KRW | KR#2,085/2,436 Sec#207/234 |
| Cash | 23.76B KRW | KR#1,135/2,436 Sec#81/234 |
| Current Ratio | 0.67x | KR#2,146/2,436 Sec#204/234 |
| Performance | ||
| 1Y Return | 276.67% | KR#27/2,436 Sec#1/234 |
| 1M Return | 7.36% | KR#360/2,436 Sec#26/234 |
| From 52W High | -64.52% | KR#1,932/2,436 Sec#164/234 |
| 1Y MDD | -97.70% | KR#2,436/2,436 Sec#234/234 |
| Trading | ||
| Volume | 44,564 shares | KR#1,408/2,436 Sec#139/234 |
| Foreign Own. | 2.41% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -9,919 KRW | KR—/2,436 Sec—/234 |
| BPS | 16,437 KRW | KR#606/2,436 Sec#39/234 |
Company Info
Aprogen Biologics, founded in 1960, absorbed an affiliate with biopharmaceutical production facilities and technology in 2022, and also incorporated N2TEC, a semiconductor equipment component manufacturer and seller, as a subsidiary. The company's core businesses include pharmaceutical and bio divisions focused on medicine manufacturing and sales, as well as semiconductor equipment component production. Its Osong factory boasts the world's fifth-largest antibody production capacity and collaborates with Aprogen on the production and commercialization of biosimilar medicines. Aprogen Biologics is headquartered in Songpa-gu, Seoul.